Anti-inflammatory agents after hip and shoulder arthroplasty: A systematic review and meta-analysis .

Pak J Pharm SciSep 9, 2026
Clinical ResearchOrthopedic Surgery

Huang Ling, Zhang Yu, Deng Shu

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the effects of perioperative anti-inflammatory agents on postoperative outcomes in adults undergoing hip and shoulder arthroplasty. Analyzing nine randomized controlled trials with 800 patients, the study found that these interventions significantly reduced postoperative C-reactive protein and interleukin-6 levels, as well as pain and hospital stay duration.

Key findings

  • Anti-inflammatory interventions reduced postoperative C-reactive protein by WMD=-32.18.
  • Interleukin-6 levels decreased significantly with a WMD of -31.25.
  • Rest pain was reduced with a WMD of -0.41.
  • Hospital stay was shortened by a WMD of -0.54.

Why it matters

Understanding the impact of anti-inflammatory agents on postoperative recovery can help clinicians optimize pain management and enhance recovery protocols for patients undergoing hip and shoulder arthroplasty.

Source

Published in Pak J Pharm Sci. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Orthopedic Surgery

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.